Table 1.
Patient Characteristics at Index Date
| Characteristic | Cohort 1: BP‐naïve patients | Cohort 2: BP‐treated patients |
|---|---|---|
| (n = 11,973) a | (n = 3422) | |
| Age (years), mean (SD), IQR | 68.2 (8.5), 13.0 | 71.5 (8.6), 13.0 |
| Age groups, n (%) | – | – |
| <75 years | 9009 (75.2) | 2066 (60.4) |
| ≥75 years | 2964 (24.8) | 1356 (39.6) |
| BMD T‐score, mean (SD), IQR | – | – |
| Total hip | −1.4 (1.2), 1.5 | −1.7 (1.1), 1.4 |
| Lumbar spine b | −1.4 (1.6), 1.9 | −1.7 (1.5), 1.8 |
| Total hip BMD T‐score < −2.5, n (%) | 1874 (15.7) | 772 (22.6) |
| Total hip BMD T‐score range, n (%) | – | – |
| < −4.0 | 122 (1.0) | 61 (1.8) |
| ≥ −4.0 to < −3.5 | 214 (1.8) | 87 (2.5) |
| ≥ −3.5 to < −3.0 | 510 (4.3) | 215 (6.3) |
| ≥ −3.0 to < −2.5 | 1028 (8.6) | 409 (12.0) |
| ≥ −2.5 to < −2.0 | 1660 (13.9) | 588 (17.2) |
| ≥ −2.0 to < −1.5 | 2113 (17.7) | 687 (20.1) |
| ≥ −1.5 to < −1.0 | 2080 (17.4) | 588 (17.2) |
| ≥ −1.0 to < −0.5 | 1750 (14.6) | 382 (11.2) |
| ≥ −0.5 | 2496 (20.9) | 405 (11.8) |
| History of prior fracture, n (%) | – | – |
| Any | 4407 (36.8) | 1176 (34.4) |
| Nonvertebral | 4138 (34.6) | 1012 (29.6) |
| Time since most recent fracture (days), mean (SD), IQR | – | – |
| Any | 586 (867), 619 | 1238 (1046), 1659 |
| Nonvertebral | 611 (886), 681 | 1315 (1057), 1645 |
| Osteoporosis treatment within 12 months before index date, n (%) c | 790 (6.6) | 2810 (82.1) |
| Assisted drug dispensing within 12 months before index date, n (%) d | 313 (2.6) | 98 (2.9) |
| Exposure to drugs that increase the risk of falls within 12 months before index date, n (%) | 8137 (68.0) | 2446 (71.5) |
| Glucocorticoid use per FRAX definition within 12 months before index date, n (%) e | 1374 (11.5) | 864 (25.3) |
| Initiation of BP‐treatment during follow‐up, n (%) | 4188 (35.0) | – |
| Initiation of BP‐treatment during follow‐up before occurrence of first fracture, n (%) | 4090 (34.2) | – |
| Charlson‐Quan comorbidity index score, n (%) | – | – |
| 0 | 8100 (67.7) | 2028 (59.3) |
| 1 | 3523 (29.4) | 1316 (38.5) |
| ≥2 | 350 (2.9) | 78 (2.3) |
Percentages may not sum due to rounding.
BMD = bone mineral density; BP = bisphosphonate; FRAX = Fracture Risk Assessment Tool; IQR = interquartile range; SD = standard deviation.
a
Patients had not received BP treatment for at least 12 months prior to index date.
b
n = 11,891 for Cohort 1 and n = 3393 for Cohort 2.
c
Includes all prior osteoporosis treatments (not exclusively BPs) within the specified timeframe.
d
Used as a proxy for dependency.
e
Exposure to ≥450 mg prednisone (or equivalent dose of other glucocorticoids).